Harrow, Inc.

HROW

US4158581094

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
17.95 ^USD	+0.62%		+0.34%	+60.27%

May. 15	B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	MT
May. 14	Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024

Harrow to Present at Two Investor Conferences in May

May 16, 2024 at 10:20 am EDT

NASHVILLE - Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA)

Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings

Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024

Craig-Hallum 21st Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)

Format: 1x1 and Small Group Investor Meetings

Date/Time: Wednesday, May 29, 2024

Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year.

Contact:

Jamie Webb

Email: jwebb@harrowinc.com

Tel: 615-733-4737

Latest news about Harrow, Inc.

B. Riley Raises Price Target on Harrow Health to $29 From $26, Keeps Buy Rating	May. 15	MT
Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours	May. 13	MT
Harrow, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial	May. 13	CI
Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
Top Midday Decliners	Mar. 20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow, Inc. Announces Board of Director Appointments	Jan. 29	CI
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division	Jan. 03	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	Jan. 03	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03	MT
Harrow, Inc.(NasdaqGM:HROW) dropped from S&P Pharmaceuticals Select Industry Index	Dec. 18	CI
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	Nov. 29	CI
Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday	Nov. 14	MT
Top Premarket Decliners	Nov. 14	MT

Chart Harrow, Inc.

Duration

Period

More charts

Company Profile

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Sector

Pharmaceuticals

Calendar

2024-06-14 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harrow, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.95 USD

Average target price

26.9 USD

Spread / Average Target

+49.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARROW, INC.	+60.27%	635M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals

Harrow, Inc.

Equities

HROW

US4158581094

Pharmaceuticals

Harrow to Present at Two Investor Conferences in May

EPS Revisions